Intel stock extends gains after report of possible U.S. government stake
In a turbulent market environment, Acadia Healthcare Company, Inc. (NASDAQ:ACHC) has seen its stock price touch a 52-week low, dipping to $32.85. According to InvestingPro analysis, this represents a significant opportunity, as analysts have set price targets ranging from $43 to $78. This latest price level reflects a significant downturn from previous periods, marking a stark contrast to the company’s performance over the past year. Acadia Healthcare, a leading provider of behavioral healthcare services, has experienced a substantial decline of -51.76% in its stock value over the past year. Despite the price decline, the company maintains strong fundamentals with a P/E ratio of 13.3 and a healthy gross profit margin of 43.1%. Investors are closely monitoring the company’s strategic moves and market conditions, as the stock navigates through these challenging financial waters. For comprehensive analysis and additional insights, including Fair Value estimates and growth projections, explore the detailed Pro Research Report available on InvestingPro.
In other recent news, Acadia Healthcare reported fourth-quarter earnings that did not meet analyst expectations, with adjusted earnings per share of $0.64 falling short of the $0.72 consensus estimate. Revenue for the quarter reached $774.2 million, marking a 4.2% year-over-year increase but still below the projected $780.22 million. The company also provided guidance for 2025, forecasting earnings per share between $2.50 and $2.80, significantly lower than Wall Street’s expectation of $3.36. Acadia anticipates 2025 revenue between $3.3 billion and $3.4 billion, which is less than the $3.43 billion consensus.
Barclays (LON:BARC) recently downgraded Acadia Healthcare’s stock rating from Overweight to Equal Weight, with analyst Andrew Mok lowering the price target from $43.00 to $35.00. This decision was influenced by various concerns, including a decrease in revenue per patient day and uncertainty surrounding several facilities affected by media coverage. Barclays also reduced its EBITDA estimates for Acadia by $60 million for 2025 and by $90 million for 2026. Despite these challenges, Acadia’s CEO, Chris Hunter, noted the company’s record annual revenue of $3.2 billion and the addition of 577 newly licensed beds in the fourth quarter. The company has also authorized a new $300 million share repurchase program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.